Immunic, Inc. (NASDAQ:IMUX) Receives $6.60 Consensus PT from Analysts

Immunic, Inc. (NASDAQ:IMUX) has earned an average rating of “Buy” from the nine research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $6.00.

A number of equities research analysts have issued reports on the company. D. Boral Capital reduced their price target on Immunic from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Brookline Capital Acquisition raised shares of Immunic to a “strong-buy” rating in a report on Tuesday, February 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunic in a research note on Monday, December 29th. Roth Mkm assumed coverage on shares of Immunic in a research report on Friday, November 7th. They issued a “buy” rating and a $3.00 price objective on the stock. Finally, Chardan Capital raised shares of Immunic to a “strong-buy” rating in a research report on Wednesday, November 19th.

Hedge Funds Weigh In On Immunic

Several hedge funds have recently made changes to their positions in the company. Nantahala Capital Management LLC purchased a new position in Immunic during the 4th quarter worth $2,337,000. Vanguard Group Inc. boosted its holdings in Immunic by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock valued at $3,832,000 after purchasing an additional 219,957 shares in the last quarter. Laurion Capital Management LP raised its stake in shares of Immunic by 106.3% during the 4th quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock worth $2,072,000 after buying an additional 2,000,000 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Immunic by 544.6% in the fourth quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after buying an additional 2,888,829 shares in the last quarter. Finally, Focus Partners Wealth grew its holdings in Immunic by 1.5% during the third quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock worth $2,276,000 after acquiring an additional 39,063 shares during the period. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Key Immunic News

Here are the key news stories impacting Immunic this week:

• Positive Sentiment: HC Wainwright raised several near‑ and mid‑term estimates (Q3 2026 and Q4 2026 upgrades and an improved FY2026 view to -$0.63 and FY2027 to -$0.50), signaling slightly better expected performance later in 2026 and beyond. HC Wainwright estimate upgrades
• Neutral Sentiment: Immunic will present at the Leerink Partners Global Healthcare Conference (fireside chat on March 11) and hold one‑on‑one investor meetings — this increases near‑term visibility but does not by itself change fundamentals. Watch for comments on pipeline progress and cash/runway commentary. Immunic to present at healthcare investor conferences in March
• Negative Sentiment: HC Wainwright trimmed several near‑term and longer‑term forecasts (cuts to Q1 and Q2 2026, downgrades to FY2028 and FY2029 EPS) and noted adjustments that reflect a slower path to profitability. Those downward revisions temper near‑term expectations. HC Wainwright estimate cuts
• Negative Sentiment: HC Wainwright set a $5.00 price target (reported as a reduction to that PT), which, while still showing sizeable theoretical upside versus current levels, may be perceived as a trimmed outlook versus prior targets and could limit immediate upside momentum. HC Wainwright Lowers Immunic Price Target to $5.00

Immunic Price Performance

Immunic stock opened at $1.17 on Thursday. The firm has a 50 day simple moving average of $0.73 and a 200-day simple moving average of $0.77. The stock has a market cap of $152.64 million, a price-to-earnings ratio of -1.67 and a beta of 1.46. Immunic has a 1-year low of $0.51 and a 1-year high of $1.35.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Equities analysts expect that Immunic will post -0.94 earnings per share for the current fiscal year.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.